Patient advocacy platform Baba has made its public debut with $6.5 million in seed led by General Catalyst, the company disclosed last week.

Amid rising healthcare costs and shrinking government coverage, two major patient assistance charities have announced a strategic merger they say will help ramp up aid.  | The Patient Advocate ...

The merger will create a foundation with more than $800 million in assets to help patients afford drug copays and navigate health insurance.

Patient Advocate Foundation and PAN Foundation today announced a strategic merger to create the nation's most comprehensive nonprofit dedicated to helping patients navigate, access, and afford care, ...

STAT now publishes selected Letters to the Editor received in response to First Opinion essays to encourage robust, good-faith discussion about difficult issues. Submit a Letter to the Editor here, or ...

The Patient Advocate Foundation and the PAN Foundation have announced a strategic merger to create the nation’s most ...

When faced with a loved one’s progressive neurodegenerative disease, like Alzheimer’s, or your child’s rare respiratory disease, you question why researchers and resource-backed pharma cannot bring a ...

Receiving a breast cancer diagnosis can be a life-altering experience, and it can also feel like you’re the only one going through this. But about 316,950 new cases of invasive breast cancer will be ...

To read the full recap, click here. Marking 12 years of the Patients as Partners in Clinical Research conference, senior leaders in pharma R&D, the FDA and patient advocacy presented examples of ...

Please provide your email address to receive an email when new articles are posted on . The world of drug development and commercialization relies heavily on industry stakeholders, as well as the ...

Sign up for the Concord Monitor’s morning newsletter for essential news each day, and our contests and promotions list for special offers and giveaways. Migraine is ...

NervGen Pharma Corp. (“NervGen” or the “Company”) (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury ...